Search research articles
Contact Us
Filters
Showing results (81-90 of 180) with videos related to
Page
of 18
Sort By:
Gynecologic Oncology Reports
|
October 29, 2025
Successful treatment of gynecologic malignancy with trastuzumab deruxtecan in three patients with <i>HER2</i> mutations
Divya S Choudhury, Katherine C Kurnit, S Diane Yamada, et al.
Gynecologic Oncology
|
June 11, 2021
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial
Carol Aghajanian, Michael A Bookman, Gini F Fleming, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2002
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661
Gini F Fleming, Neal J Meropol, Gary L Rosner, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2013
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
Joyce F Liu, Sara M Tolaney, Michael Birrer, et al.
Breast Cancer Research and Treatment
|
April 23, 2013
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer
Cynthia X Ma, Vera J Suman, Matthew Goetz, et al.
Breast Cancer Research and Treatment
|
February 10, 2025
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer
Nan Chen, Margarite Matossian, Poornima Saha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2022
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
Pamela N Munster, Andrew E Greenstein, Gini F Fleming, et al.
Gynecologic Oncology
|
February 9, 2025
Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial
Iris L Romero, Ernst Lengyel, Andrea E Wahner Hendrickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2011
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies
Tara C Gangadhar, Ezra E W Cohen, Kehua Wu, et al.
JAMA Network Open
|
March 30, 2023
Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer
Fangyuan Zhao, Minoru Miyashita, Masaya Hattori, et al.
Page
of 18
Search research articles
Search
Showing results (81-90 of 180) with videos related to
Sort By:
Page
of 18
Gynecologic Oncology Reports
|
October 29, 2025
Successful treatment of gynecologic malignancy with trastuzumab deruxtecan in three patients with <i>HER2</i> mutations
Divya S Choudhury, Katherine C Kurnit, S Diane Yamada, et al.
Gynecologic Oncology
|
June 11, 2021
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial
Carol Aghajanian, Michael A Bookman, Gini F Fleming, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2002
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661
Gini F Fleming, Neal J Meropol, Gary L Rosner, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2013
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
Joyce F Liu, Sara M Tolaney, Michael Birrer, et al.
Breast Cancer Research and Treatment
|
April 23, 2013
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer
Cynthia X Ma, Vera J Suman, Matthew Goetz, et al.
Breast Cancer Research and Treatment
|
February 10, 2025
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer
Nan Chen, Margarite Matossian, Poornima Saha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2022
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
Pamela N Munster, Andrew E Greenstein, Gini F Fleming, et al.
Gynecologic Oncology
|
February 9, 2025
Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial
Iris L Romero, Ernst Lengyel, Andrea E Wahner Hendrickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2011
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies
Tara C Gangadhar, Ezra E W Cohen, Kehua Wu, et al.
JAMA Network Open
|
March 30, 2023
Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer
Fangyuan Zhao, Minoru Miyashita, Masaya Hattori, et al.
Page
of 18